TheStreet upgraded shares of Coherus Biosciences (NASDAQ:CHRS) from a d- rating to a c- rating in a report issued on Thursday morning, TheStreetRatingsTable reports.
A number of other equities research analysts have also issued reports on the company. Barclays set a $31.00 target price on Coherus Biosciences and gave the stock a buy rating in a research report on Monday, August 12th. Zacks Investment Research raised Coherus Biosciences from a hold rating to a buy rating and set a $18.00 target price on the stock in a research report on Thursday. ValuEngine lowered Coherus Biosciences from a sell rating to a strong sell rating in a research report on Thursday, October 10th. Maxim Group reaffirmed a buy rating and set a $27.00 target price (up from $25.00) on shares of Coherus Biosciences in a research report on Friday, August 2nd. Finally, BidaskClub lowered Coherus Biosciences from a hold rating to a sell rating in a research report on Wednesday, October 16th. Two research analysts have rated the stock with a sell rating and eight have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus target price of $30.38.
Shares of NASDAQ CHRS traded up $0.06 during trading on Thursday, reaching $19.06. The stock had a trading volume of 1,353,200 shares, compared to its average volume of 992,812. The stock has a market cap of $1.14 billion, a PE ratio of -5.92 and a beta of 2.90. The firm’s 50 day moving average price is $19.20 and its two-hundred day moving average price is $19.18. Coherus Biosciences has a one year low of $8.32 and a one year high of $23.91.
In related news, COO Vincent R. Anicetti sold 2,500 shares of the company’s stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $19.00, for a total transaction of $47,500.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Jean-Frederic Viret sold 6,318 shares of the company’s stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $21.71, for a total value of $137,163.78. Following the transaction, the chief financial officer now directly owns 14,831 shares in the company, valued at $321,981.01. The disclosure for this sale can be found here. Insiders have sold 25,264 shares of company stock worth $504,967 over the last ninety days. 18.20% of the stock is owned by insiders.
A number of large investors have recently bought and sold shares of the stock. HighTower Advisors LLC raised its position in Coherus Biosciences by 6.4% during the second quarter. HighTower Advisors LLC now owns 12,184 shares of the biotechnology company’s stock valued at $268,000 after buying an additional 734 shares during the period. Cutler Group LP acquired a new position in Coherus Biosciences during the third quarter valued at $32,000. United Services Automobile Association raised its position in Coherus Biosciences by 0.9% during the second quarter. United Services Automobile Association now owns 217,216 shares of the biotechnology company’s stock valued at $4,800,000 after buying an additional 1,950 shares during the period. Tower Research Capital LLC TRC acquired a new position in Coherus Biosciences during the third quarter valued at $52,000. Finally, Brown Advisory Inc. raised its position in Coherus Biosciences by 0.5% during the second quarter. Brown Advisory Inc. now owns 656,455 shares of the biotechnology company’s stock valued at $14,508,000 after buying an additional 3,061 shares during the period. 96.37% of the stock is currently owned by hedge funds and other institutional investors.
About Coherus Biosciences
Coherus BioSciences, Inc, a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States.
Recommended Story: Call Option
Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.